Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells - Wikidata - thesis-toulmin - TriplyDB

Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells

Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells

http://www.wikidata.org/entity/Q28273155

about

Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond network Direct and indirect mechanisms of KLK4 inhibition revealed by structure and dynamics.Evolutionary history of tissue kallikreins The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention.Genetic association of the KLK4 locus with risk of prostate cancer.The role of epithelial plasticity in prostate cancer dissemination and treatment resistance Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.Male reproductive cancers and infertility: a mutual relationship.Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study Clinical significance of kallikrein-related peptidase-4 in oral cancer Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models Hepatocyte growth factor increases the invasive potential of PC-3 human prostate cancer cells via an ERK/MAPK and Zeb-1 signaling pathway.The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition.Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs).Development of peptides specifically modulating the activity of KLK2 and KLK3.New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.Functional roles of human kallikrein-related peptidases.Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Targeting kallikrein-related peptidases in prostate cancer.Unleashing the therapeutic potential of human kallikrein-related serine proteases.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma.Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells KLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/β-catenin signaling pathway.Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo.Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug.Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells.

P2860

Q26771266-2A8A850F-1CBF-4E6E-9870-03DE36552B0D Q28241633-34ECC282-EEA2-4FFC-93E0-72D1DE06133D Q28740672-5611DC1C-60A3-4623-BC9A-AD897C4DAD2D Q30825171-A83BDBF4-5032-48A0-8880-343E0D194B45 Q33745045-8060F031-EBEA-4491-8CEC-62B65688B15D Q34187693-67FB2412-F3D7-488B-A9C0-DE568A9244F8 Q34284428-219E286C-64EC-45D4-B18E-A7C2F1D0B1D6 Q34412503-3F05D13E-B7D9-49F1-BD02-0DC1BBB6EBC0 Q34505037-BC4330FA-07B7-41EA-88CA-4A0333B45D33 Q34545163-05DBB8E1-BA48-4820-A448-7D887ABA9D94 Q35048230-2E850FB6-AB14-475B-A5AC-BA30E5F0A8EE Q35585478-5A28B0DD-3D9E-4070-8CC4-0AA171B6D857 Q35637218-2D55DF08-1E42-4B7A-BF77-D350E519FAE2 Q36079284-66E71564-E0F3-461F-A291-BA6575AECD3D Q36435777-6775EB72-675B-4B12-A7E4-CEF5D8BF6FE8 Q36502905-042B5311-9EE6-4CE5-9E8C-58E0EC65F4FD Q36519383-6A0C0A98-628F-4934-9A9A-2DA8223FCEAB Q36857803-EB414742-CC90-4752-919D-F8813C86AB39 Q37010879-C6B19160-1700-41B6-A7C2-371D7BBC6F40 Q37216570-DC48B7E0-9984-4D12-B1D9-5172133D3F07 Q37216674-E61031E7-1357-408E-8A29-F800ACD2786D Q37453804-D13A89E3-8B9B-4BF1-8C07-0FF965DF30BF Q37612613-63A00E31-8579-49EB-A0DC-E8B9072A7E60 Q37690308-B23089D4-77D0-4712-8A66-0DE80EA1E37B Q37728684-E832FC92-0D5A-47D2-90AD-B62864BA1EE2 Q38184632-54087654-84B5-421B-BB52-EAFE75A11E66 Q38191293-44D33A08-EA6C-4B9E-9D76-E4D6797D46E0 Q38362486-11D56D84-ABC7-463A-B884-D1E5FC7B7331 Q38413737-E8A97A33-2DB6-492E-B117-4B32C0018B31 Q38415467-44EAF932-0B40-40BE-8537-BDEFA62878DB Q38703356-294914D2-62E2-4EFB-8BD9-64A2E0F6BD6F Q38718409-C097E09F-395A-491A-819B-7EA3AFF53F7B Q38737293-1CC45D14-FB9F-4D67-A017-A8C798011B71 Q38760061-2774A5EF-1865-4859-88F0-C24FB4682C41 Q38967490-26C082E9-4C41-4A7B-BADC-61DE2C5A6043 Q39080408-AF9256F0-7CF8-47A0-BA37-2C7307966CFA Q39493165-B6984545-5901-492A-A0D0-E15EB05E20A6 Q39552861-EFC36C1D-072B-4BA7-A26F-29BFE09704E1 Q39592007-79FC68CA-EFF2-4B40-94E3-386DCFEE9DEB Q39735812-D5B76894-3CE6-49AD-AB73-72216CDA17A9

P2860

Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells

http://www.wikidata.org/entity/Q28273155

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@ast

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@en

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@nl

type

label

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@ast

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@en

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@nl

prefLabel

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@ast

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@en

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@nl

P1433

Q28273155-2DDC742A-6E52-40C3-A25C-D5049DD22196

P1476

Q28273155-7DC0FED8-0A2C-4049-9C9E-6DBC12E1A658

P2093

Q28273155-0DC1D481-79E5-4251-BA48-312F24CD8A70

Q28273155-21B35AE6-DE91-4C80-92F8-6DFFC7D4F385

Q28273155-546A8E9A-407A-4958-9133-942AB5B20E2C

Q28273155-755B8E43-FE80-47D0-A943-814AD480B449

Q28273155-8B23160E-2CFF-473D-9527-3D065B0E554A

Q28273155-A9AD3B8D-1FCE-4B38-A4FD-DD6FB90FC698

Q28273155-E712473E-5A2A-4F02-BD80-0FC28B493588

P304

Q28273155-E63927AB-5957-4CCC-9D19-F534749DBCB5

P31

Q28273155-AA6849E9-A873-4C34-99A0-DD6A1DCB82FD

P3181

Q28273155-C10DFA2E-9E21-460C-9A13-34DC248120C3

P356

Q28273155-3C65EC66-8C2C-4954-AD99-E0C79CDE46CF

P407

Q28273155-49D32C4E-B28B-4313-A7A8-45AAF8A010CA

P433

Q28273155-2615A273-D881-4100-9FE6-09CB83D9E1AE

P478

Q28273155-A7C340D0-55D8-45A0-BCEB-AD6CEA8AA37C

P577

Q28273155-B904770B-2801-4156-9295-19F79DC98087

P5875

Q28273155-C165FA06-5B3E-452E-82C8-69DC372FEC1D

P698

Q28273155-FB9F3722-F6A0-4C4F-B0C8-82D2EE22F840

P3181

P356

P1433

Endocrine-related cancer

P1476

Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells

@en

P2093

A C Herington

http://www.w3.org/2001/XMLSchema#string

D L Nicol

http://www.w3.org/2001/XMLSchema#string

J A Clements

http://www.w3.org/2001/XMLSchema#string

L Bui

http://www.w3.org/2001/XMLSchema#string

M G Lawrence

http://www.w3.org/2001/XMLSchema#string

R L Collard

http://www.w3.org/2001/XMLSchema#string

T L Veveris-Lowe

http://www.w3.org/2001/XMLSchema#string

P304

631-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2869696

http://www.w3.org/2001/XMLSchema#string

P356

10.1677/ERC.1.00958

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7591992

http://www.w3.org/2001/XMLSchema#string

P698

16172196

http://www.w3.org/2001/XMLSchema#string